Methyl-cantharidimide suppresses cyclin-dependent kinase 1 (CDK1) and induces oxeiptosis in liver cancer

Abstract Background Methyl-cantharidimide (MCA), a cantharidin (CTD) analog, has been approved in China for the clinical treatment of liver cancer. Previous studies have shown that MCA can induce both apoptosis and cell cycle arrest in cancer cells. However, the precise molecular mechanisms underlyi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yi-Dong Li, Xiang Chen, Xing-Duo Dong, Zhiyong Ding, Zhe-Sheng Chen, Shuo Fang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2026-03-01
coleção:	Journal of Experimental & Clinical Cancer Research
Assuntos:	Methyl-cantharidimide (MCA) Liver cancer CDK1 Oxeiptosis
Acesso em linha:	https://doi.org/10.1186/s13046-026-03669-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!